Roche's Drug Pipeline Is Deeper Than Market Assumes -- Market Talk

1459 GMT - Roche Holding's base business is gaining momentum and its drug pipeline offers deeper potential than the market gives it credit for, RBC Capital Markets analysts write in a research note. The crown jewel in the Swiss drugmaker's portfolio is breast-cancer drug candidate giredestrant, which could generate annual sales of as much as $14 billion, according to RBC. Giredestrant has the potential to become a cornerstone therapy in breast cancer, the analysts say. But other drugs in Roche's pipeline such as enicepatide for obesity, pegozafermin for fatty liver disease and fenebrutinib for multiple sclerosis could see upgrades to consensus expectations, they add. RBC starts coverage on Roche with an outperform recommendation and a target price of 400 Swiss francs.Shares fall 0.8% to 347.70 francs. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

September 09, 2026 10:59 ET (14:59 GMT)